Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics


Cardiff Oncology, Inc. (CRDF): $1.60

0.02 (+1.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRDF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRDF POWR Grades

  • CRDF scores best on the Sentiment dimension, with a Sentiment rank ahead of 46.03% of US stocks.
  • The strongest trend for CRDF is in Quality, which has been heading down over the past 179 days.
  • CRDF ranks lowest in Momentum; there it ranks in the 4th percentile.

CRDF Stock Summary

  • With a price/sales ratio of 173.79, CARDIFF ONCOLOGY INC has a higher such ratio than 98.35% of stocks in our set.
  • With a year-over-year growth in debt of 629.41%, CARDIFF ONCOLOGY INC's debt growth rate surpasses 96.8% of about US stocks.
  • The volatility of CARDIFF ONCOLOGY INC's share price is greater than that of 94.02% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to CARDIFF ONCOLOGY INC, a group of peers worth examining would be LXRX, TGTX, BCDA, EXEL, and FULC.
  • Visit CRDF's SEC page to see the company's official filings. To visit the company's web site, go to www.cardiffoncology.com.

CRDF Valuation Summary

  • CRDF's price/sales ratio is 177.1; this is 3708.6% higher than that of the median Healthcare stock.
  • Over the past 186 months, CRDF's price/sales ratio has gone down 2109.7.

Below are key valuation metrics over time for CRDF.

Stock Date P/S P/B P/E EV/EBIT
CRDF 2022-09-23 177.1 0.6 -1.8 -1.3
CRDF 2022-09-22 185.2 0.6 -1.9 -1.4
CRDF 2022-09-21 194.0 0.6 -2.0 -1.5
CRDF 2022-09-20 195.3 0.6 -2.0 -1.5
CRDF 2022-09-19 195.3 0.6 -2.0 -1.5
CRDF 2022-09-16 178.4 0.6 -1.8 -1.3

CRDF Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at 57.21%.
  • The 2 year net income to common stockholders growth rate now stands at -105.32%.
  • Its year over year price growth rate is now at -85.13%.
Over the past 49 months, CRDF's revenue has gone down $136,304.

The table below shows CRDF's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.384 -29.799 -37.815
2022-03-31 0.361 -27.405 -34.129
2021-12-31 0.359 -23.04 -28.315
2021-09-30 0.345255 -20.77394 -25.47011
2021-06-30 0.395656 -18.83417 -23.0537
2021-03-31 0.370289 -18.82433 -23.68777

CRDF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRDF has a Quality Grade of D, ranking ahead of 16.71% of graded US stocks.
  • CRDF's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
  • OTIC, AVDL, and CORT are the stocks whose asset turnover ratios are most correlated with CRDF.

The table below shows CRDF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 1 -0.388
2021-03-31 0.004 1 -0.758
2020-12-31 0.007 1 17.949
2020-09-30 0.014 1 22.880
2020-06-30 0.015 1 50.452
2020-03-31 0.028 1 -56.954

CRDF Price Target

For more insight on analysts targets of CRDF, see our CRDF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

CRDF Stock Price Chart Interactive Chart >

Price chart for CRDF

CRDF Price/Volume Stats

Current price $1.60 52-week high $7.32
Prev. close $1.58 52-week low $1.13
Day low $1.54 Volume 309,600
Day high $1.63 Avg. volume 850,005
50-day MA $2.28 Dividend yield N/A
200-day MA $2.66 Market Cap 69.29M

Cardiff Oncology, Inc. (CRDF) Company Bio


Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


CRDF Latest News Stream


Event/Time News Detail
Loading, please wait...

CRDF Latest Social Stream


Loading social stream, please wait...

View Full CRDF Social Stream

Latest CRDF News From Around the Web

Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced plans to conduct a randomized Phase 2 trial of onvansertib in combination with standard-of-care (SoC) FOLFIRI/bevacizumab in second-line RAS-mutated mCRC, durability of responses from its ongoing Phase 1b/2 clinical trial in KRAS-mutated mCRC and additional business updates.

Yahoo | September 12, 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced new preclinical and clinical data from its program in KRAS-mutated mCRC. The data are featured in two posters being presented at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place at the Paris Expo Porte de Versailles in Paris, France, and virtually.

Yahoo | September 10, 2022

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference taking place in New York, NY, on September 13 – 14, 2022, and September 12 – 14, 2022, respectively.

Yahoo | September 8, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have been accepted for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place both virtually and at the Paris Expo Porte de Versailles in Paris, France from September 9 – 13, 2022.

Yahoo | September 6, 2022

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will host a webcast and conference call to provide a clinical and corporate update on Monday, September 12, 2022. The event will feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs. In addition, company manageme

Yahoo | August 29, 2022

Read More 'CRDF' Stories Here

CRDF Price Returns

1-mo -43.46%
3-mo -49.37%
6-mo -30.74%
1-year -75.76%
3-year 32.23%
5-year -97.39%
YTD -73.38%
2021 -66.59%
2020 1,350.81%
2019 -60.63%
2018 -85.80%
2017 -85.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4835 seconds.